Clinical trial
A Study of the Immunogenicity and Safety of the 2006-2007 Influenza Vaccine
NCT00343681 · Sanofi Pasteur, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00343681 |
|---|---|
| Title | A Study of the Immunogenicity and Safety of the 2006-2007 Influenza Vaccine |
| Official title | Immunogenicity and Safety of the Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2006-2007 Formulation (Intramuscular Route) |
| Lead sponsor | Sanofi Pasteur, a Sanofi Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Influenza, Orthomyxoviridae Infections |
| Intervention type | Biological |
| Interventions | Inactivated influenza vaccine (split virion) |
| Enrollment | 120 |
| Start date | Jul 1, 2006 |
| Primary completion | Aug 1, 2007 |
| Completion | Aug 1, 2007 |
| First posted | Jun 23, 2006 |
| Last update posted | Jan 17, 2014 |
| Countries | Switzerland, United Kingdom |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: